Bristol Myers Squibb Partner with Scenic Biotech to access Cell-Seq Platform

• Scenic Biotech has entered into a research collaboration with Bristol Myers Squibb to accelerate the development of Bristol Myers Squibb’s drug targets.

• Scenic Biotech will receive an upfront payment and potential additional payments contingent on the achievement of research, development, and commercial milestones.

• This collaboration marks Scenic Biotech’s second strategic collaboration with a major industry partner, following the agreement with Genentech announced in 2020.

Bristol Myers Squibb has partnered with Scenic Biotech to access their Cell-Seq technology platform. This collaboration aims to unlock the underlying genetic interactions of cellular pathways for undisclosed targets.

Scenic Biotech, a pioneer in the field of modifier therapies for severe genetic disorders, will receive an upfront payment from Bristol Myers Squibb. Additional payments are contingent upon the achievement of a range of research, development, and commercial milestones. The financial details of these milestones have not been disclosed.

Oscar Izeboud, PhD, CEO of Scenic Biotech, commented on the collaboration, saying, “Working with a world leader in drug discovery and development is an important validation of our Cell-Seq platform’s unique capability to link cellular pathways to drug targets.”

This collaboration marks Scenic Biotech’s second strategic partnership with a major industry partner, following a multi-year genetic modifier collaborative agreement with Genentech announced in 2020. Both collaborations leverage the Cell-Seq platform’s ability to provide genetic insights leading to the discovery and development of novel therapeutics.

While Scenic primarily focuses on applying its Cell-Seq technology to identify modifier genes, the technology has demonstrated its ability to map previously unexplored biological pathways and investigate disease biology. This collaboration with Bristol Myers Squibb will further enhance the application of the Cell-Seq technology in the field of contract manufacturing and CDMO.